GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » Debt-to-Asset

BioInvent International AB (OSTO:BINV) Debt-to-Asset : 0.02 (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB Debt-to-Asset?

BioInvent International AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr9.20 Mil. BioInvent International AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr8.22 Mil. BioInvent International AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was kr989.24 Mil. BioInvent International AB's debt to asset for the quarter that ended in Dec. 2024 was 0.02.


BioInvent International AB Debt-to-Asset Historical Data

The historical data trend for BioInvent International AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Debt-to-Asset Chart

BioInvent International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.02 0.02 0.02

BioInvent International AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Competitive Comparison of BioInvent International AB's Debt-to-Asset

For the Biotechnology subindustry, BioInvent International AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Debt-to-Asset falls into.


;
;

BioInvent International AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioInvent International AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(9.198 + 8.215) / 989.236
=0.02

BioInvent International AB's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(9.198 + 8.215) / 989.236
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioInvent International AB  (OSTO:BINV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


BioInvent International AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines